Abstract | BACKGROUND: The effect of upfront intensive therapy on the prognosis of older patients with metastatic castration-sensitive prostate cancer (mCSPC) remains unclear. Thus, we assessed the impact of older age (≥75 years) on oncological outcomes in mCSPC patients with a high tumor burden. METHODS: RESULTS: The 231 patients enrolled in our study were classified in the conventional group (n = 148) or the upfront group (n = 104; DTX = 27 and ABI = 77). The upfront group had significantly prolonged CRPC-FS and OS compared with the conventional group, and this was also the case in the background-adjusted multivariable Cox regression analysis. CONCLUSION: Patients aged ≥75 years who received upfront intensive therapy had significantly longer CRPC-FS and OS compared with similar age patients treated with conventional therapy in real-world practice. The oncological benefit may not diminish in this older population.
|
Authors | Yuki Miura, Shingo Hatakeyama, Shintaro Narita, Takahiro Kimura, Kenichi Hata, Takafumi Yanagisawa, Toshikazu Tanaka, Noritaka Ishi, Sadafumi Kawamura, Senji Hoshi, Shigeto Ishidoya, Koji Mitsuzuka, Akihiro Ito, Norihiko Tsuchiya, Shin Egawa, Tomonori Habuchi, Chikara Ohyama |
Journal | The Prostate
(Prostate)
Vol. 82
Issue 13
Pg. 1304-1312
(09 2022)
ISSN: 1097-0045 [Electronic] United States |
PMID | 35747992
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | © 2022 Wiley Periodicals LLC. |
Chemical References |
- Androgen Antagonists
- Docetaxel
|
Topics |
- Aged
- Androgen Antagonists
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Castration
- Docetaxel
(therapeutic use)
- Humans
- Male
- Prostatic Neoplasms
(pathology)
- Prostatic Neoplasms, Castration-Resistant
(drug therapy)
- Retrospective Studies
- Tumor Burden
|